Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Saxenda liraglutide Chronic weight management in adults Do not reimburse Complete
Scemblix asciminib Philadelphia chromosome-positive chronic myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Sebivo Telbivudine Hepatitis B (chronic) Do not list Complete
Seebri Glycopyrronium bromide Chronic obstructive pulmonary disease List with criteria/condition Complete
Segluromet ertugliflozin and metformin hydrochloride Diabetes mellitus, Type 2 Do not reimburse Complete
Semglee insulin glargine Diabetes mellitus, Type 1 & 2 Withdrawn
Sensipar Cinacalcet hydrochloride Secondary hyper-parathyroidism in chronic kidney disease Do not list Complete
Signifor Pasireotide diaspartate Cushing’s disease Do not list Complete
Siliq brodalumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Silkis Calcitriol Psoriasis, mild to moderate plaque Do not list Complete
Simbrinza Brinzolamide / brimonidine Glaucoma and ocular hypertension List Complete
Simponi Golimumab Ulcerative colitis Do not list at the submitted price Complete
Simponi Golimumab Arthritis, Rheumatoid List in a similar manner Complete
Simponi Golimumab Arthritis, psoriatic List in a similar manner Complete
Simponi Golimumab Ankylosing spondylitis List in a similar manner Complete
Simponi I.V. Golimumab Arthritis, rheumatoid List with criteria/condition Complete
Sivextro Tedizolid phosphate Acute bacterial skin and skin structure infections Withdrawn
Skyrizi risankizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Skyrizi risankizumab Crohn's disease Reimburse with clinical criteria and/or conditions Complete
Slynd drospirenone Contraceptive, oral Reimburse with clinical criteria and/or conditions Active
Sogroya somapacitan Growth Hormone Deficiency (GHD) Reimburse with clinical criteria and/or conditions Complete
Sohonos palovarotene Fibrodysplasia Ossificans Progressiva Reimburse with clinical criteria and/or conditions Complete
Soliqua lixisenatide + insulin glargine Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete
Soliris eculizumab Neuromyelitis optica spectrum disorder Reimburse with clinical criteria and/or conditions Complete
Soliris Eculizumab Hemolytic Uremic Syndrome, Atypical Do not list Complete